国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2015年
10期
1417-1419
,共3页
奥马佐单抗%过敏性支气管哮喘%疗效%安全性%系统评价
奧馬佐單抗%過敏性支氣管哮喘%療效%安全性%繫統評價
오마좌단항%과민성지기관효천%료효%안전성%계통평개
Omalizumab%Allergic bronchial asthma%Efficacy%Safety%System evaluation
目的 探讨奥马佐单抗治疗过敏性支气管哮喘的临床疗效及安全性.方法 将我院呼吸道门诊收治的112例过敏性支气管哮喘患者分为实验组和对照组,实验组给予奥马佐单抗加糖皮质激素治疗,对照组口服安慰剂或适量糖皮质激素治疗,观察两组治疗前后第1秒时间肺活量(FEV1)、最大呼气流速(PEF)、V 25％～75％等肺功能指标变化,比较两组临床疗效及不良反应.结果 两组治疗后FEV1、V25％～75％和PEF等三项肺功能指标均较治疗前有所改善(P＜0.05),但实验组改善幅度明显优于对照组(P＜ 0.05).实验组治疗总有效率93.3％,显著高于对照组的84.6％ (P＜0.05).实验组2例不良反应,对照组4例,对比差异无统计学意义(P＞0.05).结论 奥马佐单抗可有效缓解过敏性支气管哮喘症状,改善生活质量,安全性好,值得临床推广应用.
目的 探討奧馬佐單抗治療過敏性支氣管哮喘的臨床療效及安全性.方法 將我院呼吸道門診收治的112例過敏性支氣管哮喘患者分為實驗組和對照組,實驗組給予奧馬佐單抗加糖皮質激素治療,對照組口服安慰劑或適量糖皮質激素治療,觀察兩組治療前後第1秒時間肺活量(FEV1)、最大呼氣流速(PEF)、V 25％～75％等肺功能指標變化,比較兩組臨床療效及不良反應.結果 兩組治療後FEV1、V25％～75％和PEF等三項肺功能指標均較治療前有所改善(P＜0.05),但實驗組改善幅度明顯優于對照組(P＜ 0.05).實驗組治療總有效率93.3％,顯著高于對照組的84.6％ (P＜0.05).實驗組2例不良反應,對照組4例,對比差異無統計學意義(P＞0.05).結論 奧馬佐單抗可有效緩解過敏性支氣管哮喘癥狀,改善生活質量,安全性好,值得臨床推廣應用.
목적 탐토오마좌단항치료과민성지기관효천적림상료효급안전성.방법 장아원호흡도문진수치적112례과민성지기관효천환자분위실험조화대조조,실험조급여오마좌단항가당피질격소치료,대조조구복안위제혹괄량당피질격소치료,관찰량조치료전후제1초시간폐활량(FEV1)、최대호기류속(PEF)、V 25％～75％등폐공능지표변화,비교량조림상료효급불량반응.결과 량조치료후FEV1、V25％～75％화PEF등삼항폐공능지표균교치료전유소개선(P＜0.05),단실험조개선폭도명현우우대조조(P＜ 0.05).실험조치료총유효솔93.3％,현저고우대조조적84.6％ (P＜0.05).실험조2례불량반응,대조조4례,대비차이무통계학의의(P＞0.05).결론 오마좌단항가유효완해과민성지기관효천증상,개선생활질량,안전성호,치득림상추엄응용.
Objective To investigate clinical efficacy and safety of Omalizumab in the treatment of allergic bronchial asthma.Methods 112 cases of allergic bronchial asthma in respiratory department of internal medicine of our hospital were divided into experimental group and control group.Experimental group was given Omalizumab combined with glucocorticoids therapy,while control group was given placebo or moderate amount of glucocorticoids.Observed FEV1,peak expiratory flow (PEF),V25％-75％ and other changes in lung function of two groups before and after treatment,compared clinical efficacy and adverse reactions between two groups.Results After treatment,FEV1,PEF,V25％-75％ in both two groups improved (P＜0.05),and the extent of improvement in experimental group was superior to that in control group (P＜0.05).The total effective rate of experimental group was 93.3％,significantly higher than 84.6％ of control group (P＜0.05).There were 2 cases of adverse reactions in experimental group,and 4 cases in control group,without statistically significant difference (P＞0.05).Conclusion Omalizumab can efficiently relieve patients' allergic bronchial asthma symptoms,improve quality of life,which is safe,worthy of clinical application.
